prematurity

Some people believe RSV vaccines increase preterm birth risk. An unadjuvanted GSK maternal RSV vaccine trial was stopped due to more preterm births in the vaccine group. In clinical trials, more preterm births were found in those who got Abrysvo, but not at statistically significant levels. Getting the vaccine later, at 32-36 weeks, can provide protection without any risk of extreme prematurity. Additionally, post-marketing safety studies will be conducted to assess the risk of preterm births. Getting the vaccine during pregnancy can ensure the baby’s protection, especially considering Beyfortus shortages. It’s essential to weigh the benefits and risks before deciding on the timing of the vaccine.